CD33 and Miyoshi myopathy: M-MDSCs (CD11b+CD14+CD33+HLA-DRlow/−), in particular, are enriched in patients with newly diagnosed and relapsed MM compared with patients in remission, and high levels of M-MDSCs have been found to correlate with MM progression and treatment resistance [69].